Jeffrey William Pollard

The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

Cellzome Ltd. engages in the research, development, and manufacture of pharmaceutical products. It provides kinase-targeted drugs to treat inflammatory diseases. The company was founded by Gitte Neubauer on December 22, 2003 and is headquartered in Middlesex, the United Kingdom.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

AgrEvo GmbH manufacturers fertilizer products. It offers crop protection and production products including seeds, pest control products and other bio- technology products. The company is headquartered in Berlin, Germany.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Cambridge Biotechnology Ltd. is a wholly owned subsidiary of Biovitrum AB. The company's founders originate from a Pfizer Global Research & Development drug discovery team in what had previously been the Parke-Davis Neuroscience Research Centre. The founders, together with some key academic collaborators, created the company to exploit several opportunities in drug discovery as well as their world class 'gene to lead' drug discovery capability. The company has well equipped modern laboratory and office facilities situated on the Babraham Research Campus. This location allows the company to forge links with a host of world class research groups based in the Cambridge area. CBT is always looking to identify potential partner companies for both in-licensing and risk-sharing drug discovery ventures.

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

NeuroSolutions Ltd. provides flexible and skilled services to biopharmaceutical companies with a fast turnaround time. The private company is based in Coventry, UK. The British company has a large portfolio of clients, ranging from small start-ups to multinational pharmaceutical companies, which validates their quality, reliability, speed, and discretion. The company was founded by Kevin Lee. NeuroSolutions was acquired by NeuroSolutions /Private Group/ from OncoSil Medical Ltd. on August 11, 2010 for $0.72 million.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom.

Elasmogen Ltd. develops soloMER products for treatment of auto-immune mediated and inflammatory diseases. The company is headquartered in Aberdeen, the United Kingdom.

Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom.

NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom.

Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom.

Pharmenable Ltd. operates as a drug discovery company. It designs the next generation of small molecule drugs. The company was founded by Hannah Fiona Sore, Natalia Mateu, Jelena Aleksic, David Spring, and Andreas Bender in June 2016 and is headquartered in Histon, the United Kingdom.

Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom.

Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK.

Spirea Ltd. operates as a healthcare technology company. It develops smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines. The company was founded by Myriam Ouberai and is headquartered in arrogate, the United Kingdom.

Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009.

NanoSyrinx Ltd is a discovery stage biotechnology company that is based in the UK. The British company is focused on developing protein nanosyringes as a new way to deliver protein and peptide biologic drugs intracellularly. The company uses synthetic biology approaches to achieve this goal. The company was founded by Joseph Healey, Alexia Hapeshi, and Nicholas Waterfield, with Joseph Healey serving as the CEO since incorporation.

Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022.

Epidarex Exeed Ltd. is a British biotechnology company that specializes in research and experimental development. The company is based in Edinburgh, UK. The company was founded in 2019 by Elizabeth Ann Roper and Henning Steinhagen, with Henning Steinhagen serving as the CEO since its inception.

Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge.